CD8A and neoplasm: Furthermore, in lymphodepleted mice bearing B16 tumors, VSV-based therapy plus type-I IFN resistant CD8 CAR-T cells provided better tumor inhibition and higher survival rate, than type-I IFN resistant CD8 CAR-T cells alone or VSV plus wide-type CD8 CAR-T cells [143].